期刊文献+

肝癌患者A-LAK细胞与苯乙酸协同抗瘤的观察 被引量:4

The Synergistic Anti-Tumor Activity of Phenylacetate and Adherent LAK Cells from Patients with Hepatocellular Carcinoma
下载PDF
导出
摘要 目的 :简化粘附性LAK(A LAK)细胞的制备方法并观察其与苯乙酸 (PA)的协同抗瘤作用。方法 :采用苯丙氨酸甲酯(PME)处理肝癌患者外周血单个核细胞 (PBMC)而制备A LAK细胞 ;观察人肝癌SMMC772 1细胞株经PA处理后增殖能力的变化 ;并用经PA预处理的SMMC772 1培养上清液作用于A LAK细胞 ,观察A LAK增殖能力与杀伤活性的变化。结果 :采用PME制备的A LAK细胞 ,其增殖能力显著高于非粘附性LAK细胞 (NA LAK)和常规LAK细胞 ;肿瘤细胞经PA作用后 ,生长明显受到抑制 ;肿瘤细胞的培养上清液可明显抑制A LAK的增殖与杀伤活性 ,而经苯乙酸预处理的上清液则抑制作用减弱。结论 :采用PME可简便快速地制备A LAK ,而苯乙酸可与A LAK协同发挥抗瘤作用。 Objective: To improve the preparation of adherent lymphokine-activated killer cells (A-LAK cells) and to study the synergistic anti-tumor effect of phenylacetate(PA) and A-LAK cells. Methods: A-LAK cells were obtained from peripheral blood mononuclear cells (PBMC) of patients with hepatocellular carcinoma (HCC) by using L-phenylalanine methyl ester (PME) to deplete immunosuppressive monocytes. The proliferation of SMMC7721 cell line treated with PA was studied. A-LAK cells were treated with the supernatant derived from SMMC7721 cells treated with PA previously and the changes of proliferation and anti-tumor activity of A-LAK cells were observed. Results: The expansion of A-LAK cells was significantly higher than that of non-adherent LAK (NA-LAK) as well as standard LAK cells. The growth of SMMC7721 cells was significantly suppressed by PA. The supernatant of cultured tumor cells intensely suppressed the proliferation and cytotoxic activity of A-LAK cells, but the suppressive effect of supernatant treated with PA previously was decreased. Conclusion: A-LAK could be simply prepared by using PME, and have the synergistic anti-tumor effect with phenylacetate.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2001年第1期31-33,共3页 Chinese Journal of Cancer Biotherapy
基金 国家九五攻关项目! (96 90 6 0 1 2 0 )资助
关键词 粘附性LAK细胞 苯丙氨酸甲酯 肝细胞癌 苯乙酸 adherent lymphokine-activated killer cells phenylalanine methyl ester hepatocellular carcinoma phenylacetate
  • 相关文献

参考文献10

  • 1Schirrmacher V. Biotherapy of cancer: Perspectives of immunotherapy and gene therapy. J Can Res Clin Oncol, 1995, 121(8):443
  • 2叶胜龙 见: 汤钊猷 余业勤.肝癌的生物治疗[A].见: 汤钊猷,余业勤.原发性肝癌:第2版[C].上海:上海科学技术出版社,1999.382-396.
  • 3Boiardi A, Silvani A, Ruffini PA, et al. Loco-reginoal immunotherapy with recombinant interleukin-2 and adherent lymphokine-actived killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother, 1994, 39(3):193
  • 4Triozzi PL, Aldrich W, Kim J, et al. Biologic effects of the adoptive transfer of cells depleted of monocytes with L-phenylalanine methyl ester. Immunopharmacology, 1994, 28(1):39
  • 5Melden RJ, Whiteside TL, Vujanovic NL, et al. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-actived killer cells. Cancer Res, 1988, 48(12):3461
  • 6Bergman L, Schui DK, Brieger J, et al. The inhibition of lymphokine-activated killer cells in acute myeloblastic leukemia is mediated by TGF-β1. Exp Hematol, 1995, 23(14):1574
  • 7Thibout D, DiBenedetto M, Kraemer M, et al. Sodium phenylacetate modulates the synthesis of autocrine and paracrine growth factors secreted by breast cancer cell lines. Anticancer Res, 1998, 18(4A):2657
  • 8Samid D, Hudgins WR, Shack S, et al. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv Exp Med Biol, 1997, 400A:501
  • 9Thibault A, Samid D, Cooper MR, et al. Phase Ⅰ study of phenylacetate administered twice daily to patients with cancer. Cancer, 1995, 75(12):2932
  • 10Liu L, Bar-Ner M, Weber J, et al. Enhancement of tumor immunogenicity by phenylacetate and derivatives: Changes in surface antigens and tumor-derived immunosuppressive factors. Proc Am Assoc Cancer Res, 1994, 35:481

共引文献3

同被引文献55

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部